High-dose chemotherapy and autologous hematopoietic stem-cell rescue for treatment of relapsed and refractory Wilms tumor: Re-evaluating outcomes

Jenna Rossoff*, William T. Tse, Reggie E. Duerst, Jennifer Schneiderman, Elaine Morgan, Morris Kletzel, Sonali Chaudhury

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Wilms tumor (WT) treatment regimens are curative for more than 80% of patients, but those with relapsed or refractory disease continue to have poor outcomes. High-dose chemotherapy followed by autologous stem cell rescue is often utilized although outcomes remain variable. We report on HD-ASCR outcomes in 24 patients with relapsed or refractory Wilms tumor. Three-year disease free and overall survival are 46% and 60%, respectively, which is similar to those reported for conventional salvage therapies. These outcomes suggest that conventional salvage therapies should be employed for relapsed and refractory WT rather than HD-ASCR.

Original languageEnglish (US)
Pages (from-to)316-321
Number of pages6
JournalPediatric Hematology and Oncology
Volume35
Issue number5-6
DOIs
StatePublished - Aug 18 2018

Keywords

  • Autologous stem cell rescue
  • Wilms tumor
  • refractory
  • relapsed

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'High-dose chemotherapy and autologous hematopoietic stem-cell rescue for treatment of relapsed and refractory Wilms tumor: Re-evaluating outcomes'. Together they form a unique fingerprint.

Cite this